Peptide nucleic acids targeted to the amyloid precursor protein

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyloid beta (Abeta) peptide deposition in the brain is a significant factor in Alzheimer's disease (AD) pathogenesis.
• Elevated levels of Abeta, particularly Abeta(1-42), promote fibril formation, aggregation, and neuronal death, contributing to AD progression.

Purpose of the Study:

• To investigate the potential of peptide nucleic acids (PNAs) to reduce Abeta levels in the brain and plasma.
• To explore PNAs as a therapeutic strategy to slow or prevent the onset of Alzheimer's disease by targeting amyloid precursor protein (APP) and other key proteins.

Main Methods:

• Utilizing PNAs, a third-generation antisense or antigene molecule, to target messenger RNA (mRNA) or DNA.
• Employing antisense strategies to inhibit protein translation and antigene strategies to inhibit gene transcription.
• Conducting experiments with mice and rats using PNAs designed to target APP and BACE (beta-secretase 1).

Main Results:

• Ongoing studies are evaluating the efficacy of PNAs in reducing Abeta(1-40) and Abeta(1-42) levels in animal models.
• Preliminary data from ongoing studies with mice and rats are being analyzed to assess PNA effectiveness.

Conclusions:

• PNAs show promise as a novel therapeutic approach for Alzheimer's disease by targeting key proteins involved in Abeta production.
• Further research and validation are necessary to confirm the therapeutic potential of PNAs in reducing Abeta and mitigating AD progression.